Pricing Log in Create free account
Friday 6 November 2026 Export DOCS’s income statement to Excel — free account

Doximity, Inc.

DOCS Healthcare Health Information Services

Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025.

Revenue
+3.57%
EPS
−42.4%
Free cash flow
+1.87%

Quarter to September 2026, against a year earlier

32.42 0.76 −2.29%
Market cap
$5.9B
P/E
44.4×
Fwd P/E
49.7×
Dividend yield
—
F-score
5/9
Altman Z
17.11
Beneish M
−2.93
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Doximity, Inc. (DOCS) valuation and DCF model

What the price implies · reverse DCF

At $32.42 the price implies free cash flow after share-based pay growing 13.2% a year for ten years.

Free cash flow after share-based pay grew 24.9% a year over the last five years. The price asks for less than its five-year rate. The industry’s median company is priced for 14.0%.

In March 2022 the price assumed 25.2% a year; Doximity, Inc. went on to grow free cash flow after share-based pay 21.7% a year to FY2026.

Price implies
13.2%
Last 5 years, reported
24.9%
Industry median implies
14.0%

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
The price needs
13.2% a year for ten years
$32.42
today’s price
Its base case
24.9% a year for five years, then 14.9%
$52.29
61.3% above today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Doximity, Inc.’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

Today’s price implies free cash flow after share-based pay growing 13.2% a year for ten years.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Doximity, Inc.’s own cost of capital: risk-free 4.3% + beta 1.29 × equity premium 4.5% = 10.1% cost of equity; weighted, 10.1%.

Use 10.1%
Equity value $10.16b ▲ above market cap $6.30b
Base case value per share $52.29 equity value ÷ 194.31m shares
Current price $32.42 market price per share
Above today’s price 61.3% upside at the base case’s assumptions

How we got there$3.04b 10 years of cash to equity+$6.40b terminal value+$713.23m net cash=$10.16b equity value÷194.31m shares=$52.29 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Health Information Services).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 44.37× 40.77× 56.35× 21% below 42.03× 6% above
P/FCF 20.06× 27.73× 40.00× 50% below 16.74× 20% above
P/B 6.40× 6.61× 24.43× 74% below 1.87× 242% above
EV/EBITDA 23.99× 28.40× 45.57× 47% below 13.40× 79% above
EV/Sales 7.91× 10.56× 14.48× 45% below 2.63× 201% above
P/E P/FCF P/B EV/EBITDA EV/Sales
20.29×35.63×50.97×66.30×10Y avg 40.00×201920202021202220232024202520262026

DOCS trades at 20.06× P/FCF, against a 10-year average of 40.00× (range 13.72×–70.45×). That is cheaper than 88% of the last 8 year-end readings; re-rating to the average implies $64.62 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.